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ABSTRACT
Background: colorectal cancer is the third cancer cause of death
in Spain. It is important to investigate new tumoral markers for early
diagnosis, disease monitoring and prevention strategies. Telomeres
protect the chromosome from degradation by nucleases and end-
to-end fusion. The progressive loss of the telomeric ends of chro-
mosomes is an important mechanism in the timing of human cellular
aging. Telomeric Repeat Factor 1 (TRF1) is a protein that binds at
telomere ends. 
Purpose: to measure the concentrations of TRF1 and the rela-
tionships among telomere length, telomerase activity, and TRF1
levels in tumor and normal colorectal mucosa. 
Method: from normal and tumoral samples of 83 patients who
underwent surgery for colorectal cancer we analyzed TRF1 protein
concentration by Western Blot, telomerase activity, by the fluores-
cent-telomeric repeat amplification protocol assay and telomere
length by Southern Blot. 
Results: high levels of TRF1 were observed in 68.7% of tumor
samples, while the majority of normal samples (59%) showed neg-
ative or weak TRF1 concentrations. Among the tumor samples,
telomere length was significantly associated with TRF1 protein levels
(p = 0.023). 
Conclusions: a relationship was found between telomere length
and TRF1 abundance protein in tumor samples, which means that
TRF1 is an important factor in the tumor progression and maybe
a diagnostic factor. 
Key words: Telomeric repeat factor 1. Telomere length. Telom-
erase activity. Colorectal cancer.
ABBREVIATIONS
ALT: alternative lengthening of telomeres.
Kb: kilobases.
TA: telomerase activity.
TI: telomerase index.
TL: telomere length.
TPG: total product generated.
TRF1: telomeric repeat factor 1. 
TRF2: telomeric repeat binding factor 2.
INTRODUCTION
Telomeres, structures composed mostly of chromatin local-
ized at the end of eukaryotic chromosomes (1), consist of
800-3000 tandem repeats of six nucleotides (5’TTAGGG3’)
along a 5-15 kilobases (Kb) sequence (2). Telomeres protect
the chromosome from degradation by nucleases and end-to-
end fusion. The progressive loss of the telomeric ends of chro-
mosomes is an important mechanism in the timing of human
cellular aging (3). When telomeres become sufficiently short,
the majority of cells enter in senescence, but some escape
because they are able to maintain their telomere length (TL). 
Telomerase is a ribonucleoprotein that compensates for
the shortening of telomeres by adding TTAGGG repeats
onto the chromosome ends (4). In germ cells and renewing
tissues, telomerase is activated and maintains the integrity
and stability of the genome (5). Some immortalized mam-
malian cell lines and tumors maintain or increase the overall
length of their telomeres in the absence of telomerase activ-
ity (TA) by one or more mechanisms referred to as alter-
native lengthening of telomeres (ALT) (6).
Previous studies have not uncovered a direct relationship
between TA and TL (7), raising the possibility of telomere-
binding proteins that regulate TL, TA, and maintain the pro-
tective structure of the telomere in vivo (8,9). Six proteins
(TRF1, TRF2, POT1, TIN2, TPP1, and hRap1) bind at telom-
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ere ends in a complex known as shelterin. TRF1, TRF2, and
POT1 directly bind telomeric DNA. Telomeric Repeat Bind-
ing Factor 1 (TRF1) acts in cis, obstructing telomerase and
preventing telomere elongation (10). The number of molecules
of TRF1 bound to each telomere end is correlated with TL
(11). Telomeric Repeat Binding Factor 2 (TRF2) induces T-
loop structure, protecting telomeres from degradation by
exonucleases. The telomere homeostasis hypothesis predicts
that longer telomeres bind more TRF1; TRF1 obstructs telom-
erase and prevents telomere elongation (12). Short telomeres
bind fewer TRF1 molecules, favoring an open conformation
with more chances to be elongated by telomerase (13).
TL abnormalities appear to be one of the earliest preva-
lent genetic alterations acquired during the multistep process
of malignant transformation (14). By demonstrating the
participation of TRF1 in TL maintenance, we gain a useful
new biomarker to employ in early diagnostics and disease
monitoring and prevention strategies. 
In this study, we investigate whether the telomere home-
ostasis hypothesis can be directly applied to understand
various molecular characteristics of normal and cancerous
tissues. We measured TA, TL, and TRF1 protein abundance
in cancerous and noncancerous mucosal samples from 83
colorectal cancer patients. Finally, we applied statistical
techniques to determine the relationships among these three
variables and additional anatomopathological features.
PATIENTS AND METHODS
Patients
Fresh samples of cancer tissue and normal mucosa were
obtained from 83 patients (46 male, 37 female) undergoing
oncological tumor resection for colorectal cancer at Lleida
Arnau de Vilanova University Hospital. We considered nor-
mal mucosa as having a macroscopically normal appear-
ance and lying from 10 cm to the tumor. The patients ranged
in age from 45 to 89 years, with an average age of 69.3
years. No patient’s received neoadjuvant therapy. All tissue
samples weighing 100 mg were immediately frozen in liq-
uid nitrogen and stored at -80 ºC.
Samples were analyzed by the hospital’s Pathology unit.
Tumors were staged according to the tumor-node-metas-
tases classification of the International Union against Cancer
(UICC-TNM classification). Clinical and pathological data
were collected in a specific database. All research protocols
used in this study were approved by the Hospital Clinical
Research Ethics Committee, conforms Ethical Guidelines
of Helsinki Declaration. 
Evaluation of TRF1 protein concentration by
Western Blot 
Briefly, 40 mg of frozen tissue samples were homoge-
nized with 400 ml protein lysis buffer (125 mM Tris,
pH 6.8), with RNase inhibitor (RNAsin® Ribonuclease
inhibitor, Promega) added to the tumor samples. The
homogenates were centrifuged at 12,000 rpm at 4 ºC for 2
minutes, and the supernatants were sonicated (Digital soni-
fier 450 Branson) to degrade DNA. Total protein concen-
tration was determined using the Bio-Rad Micro Protein
Assay (Bio-Rad Laboratories). 25 mg of total protein were
separated by electrophoresis on 10% agarose, transferred
to a PDVF membranes (polyvinylidine fluoride, Millipore)
and incubated with 1:500 anti-TRF1 monoclonal mouse
antibody into a 5% milk solution (clone TRF-78, Sigma-
Aldrich) under the manufacturer’s recommended condi-
tions. The corresponding peroxidase-labeled secondary
anti-mouse antibody, diluted 1:12,500 (Jackson ImmunoRe-
search Laboratories), was detected using an enhanced
chemiluminescence system (EZ-ECL Chemiluminescence
Detection Kit for HRP, Biological Industries Kibbutz Beit
Haemek, Israel) and analyzed by Lumi-Imager (Boehringer
Mannheim). Levels of monoclonal anti-a-tubulin (Sigma,
Sant Louis, Missouri) used at 1/30,000 dilution were mea-
sured for protein normalization between samples. TRF1
levels were qualitatively compared with a TRF1 positive
control (cell line 293, Human embryonic kidney cells) (15). 
Levels of TRF1 protein in tumor and normal samples
were determined relative to protein levels in cell line 293,
our baseline positive control (designated “100%”). Samples
were categorized by three separate observers as follows:
“-” as low concentration relative to the positive control,
“+” as weak concentration, “++” as medium concentration,
and “+++” as high concentration. We further sub-classified
TRF1 protein levels into two groups: samples with low and
weak concentrations (-/+) and samples with medium and
high concentrations (++/+++). To determine the TRF1 ratio
we compared the protein levels in two samples from the
same patient. The ratio was positive if the TRF1 level was
higher in the tumor mucosa than the normal mucosa, and
the ratio was negative if the TRF1 level was lower in the
tumor mucosa than the normal mucosa. These TRF1 ratios
were divided into two groups: negative and equal ratios (-
/=), and positive ratios (+).
Fluorescent-telomeric repeat amplification protocol 
TA was measured quantitatively by the fluorescent-telom-
eric repeat amplification protocol assay (TRAP-F), using a
TRAPeze Telomerase Detection Kit (INTERGEN®Purchase)
(16). We report TA in TPG (total product generated). Analysis
was performed as described previously (17). Telomerase
index (TI) was determined by the formula TI = log (TA of
cancer tissue-TA of normal mucosa).
Telomere length measurement by Southern Blot 
Telomere restriction fragment (TRF) length was deter-
mined by Southern blot (Telo TAGGG Telomere length
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assay, Roche Diagnostics) in tumor and normal tissues.
Analysis was performed as described previously (18,19).
The telomere length was expressed in Kb. The telomere
length ratio (TLR) was determined as the quotient between
the TL in the tumor tissue and the TL in normal mucosa
from the same patient. Telomere shortening and elongation
were defined as TLs of carcinoma less than 80% and greater
than 120% of the corresponding normal mucosa, respec-
tively.
Statistical analysis
We used the statistical program SPSS® 18.0 for Windows
(SPSS Inc.) for analyses. Patient factors and TRF1 expres-
sion level were analyzed using the chi-square test. We used
the non-parametric Mann-Whitney U-test and Fisher test.
The cut-off TRF length ratio = 1 was chosen by means of
the classification and regression tree technique (CART). A
TI value of 0.85 was used to classify patients showing a
high index (> 0.85) and patients with low index (≤ 0.85)
and this value was estimated using maximally selected chi-
squared statistics (18). We considered results statistically
significant when p < 0.05.
RESULTS
Molecular markers differ between cancerous 
and normal tissues
The anatomopathological characteristics studied from
83 colorectal cancer patients are shown in table I. Mean TL
(Fig. 1A) in tumor samples was 6.77 kb (2.19-13.31 kb),
while in normal mucosa the average TL was 7.78 kb (4.20-
15.70 kb) (p < 0.001). The mean TA (Fig. 1B) in the tumor
samples was 12.3 TPG (0-164.87 TPG) and in normal sam-
ples it was 1.18 TPG (0-24.67 TPG) (p < 0.001). The TI
mean was 0.45. Additionally, we detected TRF1 protein in
95% and 89% of our cancerous and noncancerous samples,
respectively. The majority of normal samples (59%) showed
negative or weak TRF1 concentration, while 68.7% of
tumor samples presented high levels of TRF1. To summa-
rize, on average the cancerous samples had shorter telom-
eres, higher TA, and higher TRF1 protein levels than paired
noncancerous samples.
TRF1 protein levels are significantly related to
anatomopathological features (Fig. 2)
Two statistically significant relationships between the
anatomopathological variables and molecular tissue markers
emerged upon chi-square analysis (Tables I and II). First,
normal mucosa from male patients exhibited lower relative
TRF1 protein levels compared with the noncancerous sam-
ples from female patients (Table I, p < 0.009). Second, we
Fig. 1. Telomere length and telomerase activity in tumor and normal tissue in colorectal cancer patients. A. Telomere length levels in kb. B. Telomerase
activity in TPG in tumor and normal tissue of colorectal cancer patients (n = 83). Data are shown as mean ± standard error. In both p < 0.001.
Fig. 2. TRF1 analysis by Western Blot. A representative Western Blot analy-
sis is shown for telomeric repeat binding factor 1 (TRF1) expression in
patients (Pt) with colorectal carcinoma. Results obtained from five tumor
tissues (T) and non-tumor tissues (N) are included, and tubulin normal-
ization also is indicated. First line is a TRF1 positive control (cell line 293,
Human embryonic kidney cells).
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Table I. Relationships among TRF1 protein levels (low/weak or medium/high) and anatomopathological 
features analyzed by the Chi-square test
Variable (n) TRF1 level, tumor (%) TRF1 level, normal (%) TRF1 Ratio (%)
-/+ ++ /+++ -/+ ++/+++ -/= +
Patients (n = 83) 26 (31) 57 (69)   49 (59) 34 (41) 49 (59) 34 (41)  
Gender
Male (46) 18 (39) 28 (61)  33 (72) 13 (28)   20 (43.5) 26 (56.5)
Female (37) 8 (22) 29 (78) 16 (43) 21 (57)  17 (46) 20 (54)
p 0.087 0.009 0.822
Age (years)
≤ 70 (41) 9 (22) 32 (78) 25 (61) 16 (39) 15 (37) 26 (63)
> 70 (42) 17 (40.5) 25 (59.5) 24 (57) 18 (43) 22 (52) 20 (48)
p 0.069 0.723 0.148
Tumor site
Right colon (32) 10 (31) 22 (69) 17 (53) 15 (47) 17 (53) 15 (47)
Left colon (21) 4 (19) 17 (81) 15 (71) 6 (29) 5 (24) 16 (76)
Rectum (30) 12 (40) 18 (60) 17 (57) 13 (43) 15 (50) 15 (50)
p 0.284 0.393 0.083
Tumor histology
Adenocarcinoma (73) 23 (31.5) 50 (68.5) 45 (62) 28 (38) 31 (42.5) 42 (57.5)
Mucinous (10) 3 (30) 7 (70) 4 (40) 6 (60) 6 (60) 4 (40)
p 0.923 0.192 0.295
Macroscopic aspect
Ulcerous-infiltrative (42) 15 (36) 27 (64) 22 (52) 20 (48) 23 (55) 19 (45)
Vegetating (36) 10 (28) 26 (72) 25 (70) 11 (30) 12 (33) 24 (67)
Polypoid (5) 1 (20) 4 (80) 2 (40) 3 (60) 2 (40) 3 (60)
p 0.642 0.209 0.161
Dukes classification
A (1) 1 (100) 0 (0) 1 (100) 1 (0) 1 (100) 0 (0)
B (47) 16 (34) 31 (66) 26 (55) 21 (45) 24 (51) 23 (49)
C (24) 6 (25) 18 (75) 16 (67) 8 (33) 10 (42) 14 (58)
D (11) 3 (27) 8 (73) 6 (54.5) 5 (45.5) 2 (18) 9 (82)
p 0.410 0.652 0.156
T classification 
Tis (2) 1 (50) 1 (50) 2 (100) 0 (0) 1 (50) 1 (50)
T2 (11) 3 (27) 8 (73) 5 (45.5) 6 (54.5) 6 (54.5) 5 (45.5)
T3 (63) 20 (32) 43 (68) 35 (56) 28 (44) 29 (46) 34 (54)
T4 (7) 2 (29) 5 (71) 7 (100) 0 (0) 1 (14) 6 (86)
p 0.932 0.060 0.373
N classification
N (-) (49) 17 (35) 32 (65) 27 (55) 22 (45) 25 (51) 24 (49)  
N (+) (34) 9 (26.5) 25 (73.5) 22 (65) 12 (35) 12 (35) 22 (65)  
p 0.427 0.382 0.156
M classification
M0 (72) 23 (32) 49 (68) 43 (60) 29 (40) 35 (49) 37 (51)  
M1 (11) 3 (27) 8 (73) 6 (54.5) 5 (45.5) 2 (18) 9 (82)  
p 0.756 0.745 0.059
TNM stage
0 (2) 1 (50) 1(50) 2 (100) 0 (0) 1 (50) 1 (50)  
I (11) 3 (27) 8 (73) 5 (45.5) 6 (54.5) 6 (54.5) 4 (45.5)  
II (35) 13 (37) 22 (63) 20 (57) 15 (43) 18 (51) 17 (49)
III (24) 6 (25) 18 (75) 16 (67) 8 (33) 10 (42) 14 (58)
IV (11) 3 (27) 8 (73) 6 (54.5) 5 (45.5) 2 (18) 9 (82)
p 0.829 0.567 0.365
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found among the tumor samples, TL had a significant asso-
ciation with TRF1 protein levels (p < 0.023); this associa-
tion was not significant in the normal mucosal samples
(Table II, p < 0.651) the tumors that did not change their
TL had a high TRF1 expression than the others that elon-
gated or shorten their TL. 
TRF1 protein abundance, telomerase activity, 
and telomere length are related
We uncovered a relationship between TA (positive/neg-
ative) and TRF1 protein abundance in tumor samples: the
87.5% of tumors samples with negative TA showed medi-
um/high TRF1 protein levels, as compared with 64% of
positive telomere tumors. This result was not statically sig-
nificant (p < 0.071). Tumors with high TRF1 protein abun-
dance exhibited greater TA and longer telomeres than
tumors with lower TRF1 protein levels. In noncancerous
samples, however, the samples with low TRF1 protein lev-
els displayed higher TA and shorter telomeres than the non-
cancerous samples with high TRF1 protein abundance, a
difference that was not statistically significant (p < 0.052). 
DISCUSSION
In this study we have shown on average that cancerous
samples had shorter telomeres, higher TA, and higher TRF1
protein levels than paired noncancerous samples. While on
average tumoral mucosa display elevated TA and shorter
telomeres relative to normal mucosa, no statistically signif-
icant association between TA and TL has been identified
(8,17,20). We identified TRF1 as a candidate protein for
maintenance of telomere homeostasis. This protein, located
at the end of telomeres, maintains the T-loop structure nec-
essary to protect chromosome ends from degradation (12,21).
TRF1 has been subjected to various studies in various
tumor types (13,14,21,22). The main methodologies to study
TRF1 have been western blotting (13) and immunohisto-
chemistry (22,23). We detected TRF1 protein in 95% and
89% of our cancerous and noncancerous samples, respec-
tively. The majority of normal samples showed low or weak
TRF1 protein levels, while almost 70% of tumor samples
presented high TRF1 protein abundance. This is an unex-
pected result; although we anticipated TRF1 protein in both
tissues, we did not expect to observe elevated TRF1 levels
in tumor samples relative to normal samples, since telomeres
in tumor samples are shorter than normal mucosa and TRF1
protein was previously observed bound to the (longer) telom-
eres of normal mucosa (10,13). Given these previous studies,
we expected a direct association between TL and levels of
TRF1. This association was not identified in tumor samples
due to altered telomere homeostasis mechanisms. Generally,
in normal mucosa in people without a tumoral process, this
mucosa show a relation between TL and TRF1 levels, since
longer telomeres accept more TRF1 bound because this
binding is sequence specific. In tumoral mucosa the telomere
homeostasis was deregulated, lots of cellular mechanisms
not function well (due to a transformation process from nor-
mal to tumor cell). In addition, shorter telomeres may be
more difficult to stabilizer and need to bind higher levels of
TRF1. Whereas, in normal mucosa which has longer telom-
eres they may be easier to stabilizer and other mechanisms
which control the homeostasis of telomeres function well
and needs less TRF1 to bind. 
TRF1 protein abundance in normal mucosa showed a sig-
nificant association with gender, with more samples from
women displaying elevated protein levels. High quantity of
TRF1 upon normal mucosa means more stability for telom-
Table II. Relationships among TRF1 protein levels (low/weak or medium/high) and telomere length, 
telomere length ratio and telomerase activity analyzed by the Chi-square test
Variable (n) TRF1 level, tumor (%) TRF1 level, normal (%) TRF1 Ratio (%)
-/+ ++ /+++ -/+ ++/+++ -/= +
Patients (n = 83) 26 (31) 57 (69)   49 (59) 34 (41) 49 (59) 34 (41)  
Telomere length
Shortened (32) 15 (47 17 (53) 17 (53) 15 (47) 17 (53) 15 (47)      
Elongated (7) 3 (43) 4 (57) 4 (57) 3 (47) 4 (57) 3 (43)    
No change (44) 8 (18) 36 (82) 28 (64) 16 (36) 16 (36) 28 (64) 
p 0.023 0.651 0.273
TLR
≤ 1 (63) 21 (33) 42 (67) 38 (60) 25 (40) 26 (41) 37 (59)
> 1 (20) 5 (25) 15 (75) 11 (55) 9 (45)   11 (55) 9 (45)     
p 0.484 0.674 0.282
TI 0.85
≤ 0.85 (57) 17 (30) 40 (70) 31 (54) 26 (46)    27 (47) 30 (53)
> 0.85 (26) 9 (35) 17 (65) 18 (69) 8 (31)    10 (38.5) 16 (61.5)
p 0.662 0.202 0.449
TLR: telomere lenght ratio; TI: telomerase index.
eres and homeostasis of them. This situation determines
healthier telomeric homeostasis in females than in males. Sev-
eral studies reported that females have long telomeres than
males due to faster attrition rate in males (in people without
tumoral process) (24). Nawrot et al. (25) concluded that the
difference in gender were due to estrogen-responsive hormone
regulators in telomerase. Nawrot suggested that the process
of ageing might be an X-linked trait. TL had a significant
association with TRF1 protein levels in tumor mucosa: a high
percentage of samples with average normal TL displayed high
TRF1 protein levels. The binding of TRF1 on the telomeres
may be a protection mechanism, as it can permit a better tol-
erance to shorter telomeres during tumor progression (26).
TRF1 and TRF2 bind to the double-strand telomere DNA
together with POT1, Rap1, TIN1, and PPT to form the shel-
terin complex, protecting chromosome ends and activating
the telomere repair pathway (10). Under normal conditions,
a direct relation exists between TRF1 levels and TL (12), but
we have uncovered an indirect relation between TRF1 levels
and TL in tumor samples. If telomeres in tumor samples have
sufficient levels of bound TRF1, they may survive despite
the short telomeres. TL and TA are altered in tumors (13); this
study provides evidence that TRF1 levels are also altered in
comparison to normal tissue. Previously, the percentage of
TRF1-positive cells was correlated positively with tumor his-
tology; differentiated tumors expressed more TRF1 –more
differentiated level more TRF1 level (22). A significant neg-
ative relationship between TRF1 levels and histology degree
was observed in brain tumors (27,28). 
While we observed that, as a group, telomerase-negative
tumors displayed higher TRF1 protein levels than normal
tissue; this result did not pass our significance cutoff. Per-
haps tumors with low TA require additional mechanisms
to maintain TL; for example, many TRF1 molecules bind-
ing at the telomeres may increase survival, as suggested by
the homeostasis telomere hypothesis (6). It is now known
that TRF1 binds the telomeres lengthwise, hindering telom-
erase binding and lengthening the telomeres (10,11). Our
results agree with a previous work demonstrating that longer
telomeres recruited more TRF1 than shorter telomeres, and
that TRF1 inhibited telomerase; in other words, telomerase
tended to elongate shorter telomeres with less bound TRF1
(10). TRF1 seems to protect short telomeres short, main-
taining their integrity and promoting tumor survival. Sam-
ples with medium to high TRF1 protein abundance showed
longer telomeres than samples with low TRF1 expression
in both normal and tumor tissues. These results agree with
other studies affirming that the amount of TRF1 binding at
the telomere end is proportional to the TL (12).
The statistical analyses did not reveal significant differ-
ences TA, TL, and TRF1 protein abundance. On the one
hand, TL demonstrated a link with TRF1 protein abun-
dance; on the other, TRF1 protein levels had no significant
relation with TA. In general, we found that tumors with low
TA had long telomeres and expressed high levels of TRF1,
whereas tumors with higher TA had shorter telomeres and
expressed lower TRF1 levels. A possible explanation for
this behavior is for samples with low or no telomerase activ-
ity, a high level of TRF1 could become essential for chro-
mosome stability (11), thus affecting TA. Additionally, the
telomeres in tumor cells may display different behavior
from telomeres in normal cells, possibly as a result of pro-
tein regulation of TL and TA (8). It is known that three
sequence-specific DNA binding proteins (TRF1, TRF2,
and POT1) are recruited to chromosomal ends; they form
a functional complex that caps telomere ends and prevents
telomere dysfunction which initiates genomic changes and
promotes the development of cancer (8,14).
We propose that some tumors elongate their telomeres
using TA as opposed to ALT (6,26,29). ALT is a TL main-
tenance mechanism based on recombination, where telom-
eres use other telomeric DNA as a template for DNA syn-
thesis. ALT cells are able to elongate their telomeres without
any apparent intervention of other telomeres (30). In vitro
experiments indicate that human cells may be capable of
concomitantly utilizing both mechanisms of telomere main-
tenance without affecting growth and viability (31).
In summary, we observed that tumors that do not change
their TLs have higher TRF1 protein levels than those that
do change their TLs. We found a relationship between TL
and TRF1 protein abundance, but not with TA. Tumor sam-
ples exhibited different molecular activities related to TRF1,
TL, and TA when compared with normal samples. These
results affirm that a direct relation exists between TL and
TRF1 levels. Normal samples with elongated telomeres
exhibited higher TRF1 protein levels than samples with
short telomeres, a result coincident with the homeostasis
telomere hypothesis, whereas tumor samples whose TLs
were maintained presented higher TRF1 level. We believe
that additional studies of TRF1 will bring to light additional
key factors of cancer development. Our study concludes
that TRF1 is an important factor in the regulation of the
telomeres and TRF1 changes its behavior in cancer com-
pared in normal samples. Then it maybe an important prog-
nostic factor in the future together with telomere length and
telomerase activity.
The alteration of the mechanism of TL maintenance
(telomerase, TRF1, ALT) may represent a first step toward
the proliferation of cells leading to carcinogenesis. TRF1
is an important factor in the homeostasis of telomeres; it is
involved in both the telomerase and ALT mechanisms, since
TRF1 and TRF2 are required to form ALT structures. TRF1,
TL, and TA may therefore serve as new indicators of prog-
nosis and as markers for new anti-cancer therapies.
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